newsfilter
← Latest News
PR Newswire·

Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update

-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022- -Company to host teplizumab commercial launch investor event on Thursday, May 19, 2022- RED BANK, N.J., May 5, 202